Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Holding KYTX?
Track your performance easily
KYTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.94 - $35.06
Previous Close$3.99
Volume270.31K
Average Volume (3M)330.36K
Market Cap
$172.25M
Enterprise Value-$140.20M
Total Cash (Recent Filing)$321.59M
Total Debt (Recent Filing)$9.14M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Apr 01, 2025EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.07
Shares Outstanding43,171,612
10 Day Avg. Volume282,660
30 Day Avg. Volume330,357
Standard Deviation0.21
R-Squared0.00930
Alpha-0.18
Financial Highlights & Ratios
Price to Book (P/B)0.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda2.27
Forecast
1Y Price Target
$25.71Price Target Upside485.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Kyverna Therapeutics, Inc. News
PremiumCompany Announcements
Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D CostsPremiumCompany Announcements
Kyverna Therapeutics Advances in Cell Therapy LeadershipPremiumCompany Announcements
Kyverna Therapeutics Strengthens Board with New AppointmentBulls Say, Bears Say
Bulls Say
Clinical Trials And Treatment EfficacyKYV-101 demonstrates activity in severe lupus nephritis patients and a consistent safety profile.
Financial StabilityKyverna ended 3Q24 with roughly $322M in cash and cash equivalents, which could provide an operational runway into 2026.
Leadership And ManagementMr. Warner Biddle takes the helm as CEO, bringing over 30 years of experience in senior commercial and franchise leadership roles across various products, disease areas, and geographies.
Bears Say
Financial PerformanceKyverna reported a net loss of $0.80 per share, which exceeded the prior estimate of a net loss of $0.68 per share.
Market CompetitionCompetitor modalities, including mRNA-modified CAR-T therapies, may prove superior to the current offerings of Kyverna.
Product DevelopmentThe median measurement of UPCR for patients treated with 100M cells of KYV-101 did not achieve the desired <0.5 level, raising concerns about the efficacy of the treatment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $3.94 and its highest was $35.06 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Apr 01, 2025 which is in 129 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.014.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -$0.84.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,171,610 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went down -5.138%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Among the largest hedge funds holding Kyverna Therapeutics, Inc.’s share is Deerfield Management Company, LP. It holds Kyverna Therapeutics, Inc.’s shares valued at 4M.
---
Kyverna Therapeutics, Inc. Stock Smart Score
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
---
KYTX Stock 12 Month Forecast
Average Price Target
$25.71
▲(485.65% Upside)
Technical Analysis
Best Analysts Covering KYTX
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-48.67%
reiterated a buy rating 4 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -48.67% per trade.
---